Welcome to our dedicated page for Biocorrx news (Ticker: BICX), a resource for investors and traders seeking the latest updates and insights on Biocorrx stock.
About BioCorRx Inc. (BICX)
BioCorRx Inc. (OTCQB: BICX) is a pioneering healthcare solutions company dedicated to addressing the critical public health challenges of addiction and obesity through innovative treatment programs and clinical-stage pharmaceutical development. Headquartered in Anaheim, California, BioCorRx operates at the intersection of addiction treatment, behavioral health, and pharmaceutical innovation, offering a comprehensive suite of solutions aimed at improving patient outcomes and quality of life.
Core Business Areas
BioCorRx’s business is centered on two primary domains:
- Substance Use Disorder (SUD) Treatment: The company’s flagship offering, the BioCorRx® Recovery Program, combines a proprietary long-acting naltrexone implant with cognitive behavioral therapy (CBT) modules and peer support. This program is designed to significantly reduce cravings for alcohol and opioids, addressing the root causes of addiction while providing patients with the tools and support needed for sustainable recovery.
- Weight Loss Solutions: The UnCraveRx® Weight Loss Program incorporates medication-assisted therapy with behavioral and nutritional counseling, offering a holistic approach to combating obesity. This program leverages the company’s expertise in addiction treatment to address the behavioral aspects of weight management.
Pharmaceutical Innovation
Through its majority-owned subsidiary, BioCorRx Pharmaceuticals Inc., the company is advancing clinical-stage drug development with a focus on implantable, long-acting naltrexone therapies. The flagship product under development, BICX104, is a biodegradable naltrexone pellet designed for subcutaneous implantation. This innovative treatment aims to improve patient compliance by providing sustained therapeutic levels of naltrexone for up to 84 days, significantly reducing the risk of relapse in opioid and alcohol use disorders. BICX104 is being developed in collaboration with the National Institute on Drug Abuse (NIDA) under the NIH HEAL Initiative®, further underscoring the company’s commitment to addressing the opioid crisis.
Market Position and Differentiation
BioCorRx operates in a competitive landscape that includes traditional rehabilitation centers, pharmaceutical companies, and behavioral health providers. The company sets itself apart through its integrated approach, which combines FDA-approved medications, proprietary delivery systems, and evidence-based behavioral therapies. Its focus on long-acting, implantable treatments addresses common challenges in addiction recovery, such as medication adherence and patient compliance, offering a unique value proposition in the market.
Strategic Partnerships and Funding
BioCorRx has secured significant funding and partnerships to advance its mission. Notably, the company received a multi-year grant from NIDA to accelerate the development of BICX104 for methamphetamine use disorder (MUD), a condition with no currently approved medications. This collaboration highlights BioCorRx’s role as a trusted partner in addressing unmet medical needs and its ability to leverage external resources to drive innovation.
Commitment to Public Health
Beyond its commercial pursuits, BioCorRx is deeply committed to tackling pressing public health issues. Its programs are designed not only to treat addiction and obesity but also to alleviate the broader societal impacts of these conditions, such as healthcare costs, lost productivity, and the emotional toll on families and communities.
Future Outlook
With a robust pipeline of innovative treatments, a growing intellectual property portfolio, and strategic collaborations with leading institutions, BioCorRx is well-positioned to make a lasting impact on the fields of addiction treatment and behavioral health. The company’s ongoing efforts to secure FDA approval for BICX104 and expand its weight loss program reflect its commitment to addressing unmet medical needs and improving patient outcomes worldwide.
BioCorRx (OTCQB: BICX) has enrolled the last subject in its Phase I clinical trial for BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder (OUD). The trial, led by Dr. Joel M. Neutel, will evaluate the safety and pharmacokinetics of BICX104 compared to the monthly injection Vivitrol. Interim data is expected by year-end, with plans to add more subjects for FDA-required clinical characterization, targeting potential marketing approval in 2023. The study is conducted in collaboration with the National Institute on Drug Abuse.
BioCorRx Inc. (BICX) announced that Lourdes Felix, CEO and Director, will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The conference will be held at the Lotte New York Palace Hotel and will include both in-person and virtual attendance. Attendees can access the presentation on-demand starting September 12 at 7:00 AM ET. BioCorRx focuses on innovative treatment programs for substance abuse and related disorders, including its proprietary programs like Beat Addiction Recovery and UnCraveRx®.
BioCorRx Inc. (BICX) reported a significant milestone in its business update, having dosed its first subject in the Phase I clinical trial of BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder (OUD). Collaborating with 2B3D, the company is also piloting a unique PTSD and addiction treatment program for veterans utilizing virtual reality technology. The FDA has accepted the 505(b)(2) abbreviated pathway for BICX104, which may also seek dual indication for OUD and Alcohol Use Disorder (AUD). The Q2 2022 report is now available on their website.
BioCorRx Inc. (OTCQB: BICX) announced that Brady Granier, its President and Director, will present at the Benzinga All Access event on July 15, 2022, at 10:40 A.M. Eastern Time. This live event will focus on the company's innovative treatment programs for substance abuse disorders and related issues. Viewers can watch the presentation live on the company's YouTube channel, with an archived version available on their investor relations website. BioCorRx offers unique addiction solutions, including Cognitive Behavioral Therapy and medication-assisted treatment for weight loss.
BioCorRx announced the successful dosing of the first subject in its Phase I clinical trial for BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder (OUD). This trial marks a significant milestone in the company's efforts to address the growing opioid crisis, which saw over 107,000 overdose deaths in 2021. The study, led by Dr. Joel M. Neutel, will evaluate the safety and pharmacokinetics of BICX104 compared to traditional naltrexone injections. BioCorRx is collaborating with the National Institute on Drug Abuse and aims for dual indications for OUD and Alcohol Use Disorder.
BioCorRx Inc. (OTCQB: BICX) announced that Executive VP Tom Welch appeared on LiveNOW from FOX to discuss a pilot program in collaboration with 2B3D. This program focuses on PTSD and addiction treatment solutions for veterans using metaverse technology. BioCorRx provides innovative addiction treatment programs, including Beat Addiction Recovery and the UnCraveRx® Weight Loss Program, along with its clinical stage drug development subsidiary targeting FDA approval for BICX104, an implantable naltrexone pellet.
BioCorRx Inc. (OTCQB: BICX) announced its participation at the LD Micro Invitational XII from June 7-9, 2022. CEO Lourdes Felix and President Brady Granier will present on June 7 at 11:30 AM PT. The presentation will be available via live webcast. BioCorRx focuses on innovative treatment programs for substance abuse and related disorders, including Beat Addiction Recovery and UnCraveRx® for weight loss, featuring cognitive therapy and medication support. The company is also working on BICX104, an implantable naltrexone pellet for treating alcohol and opioid use disorders.
BioCorRx (OTCQB: BICX) has announced a collaboration with 2B3D to develop a treatment program targeting veterans suffering from PTSD and substance use disorders. This initiative integrates BioCorRx's Medication-Assisted Treatment (MAT) program with 2B3D's virtual reality technology to enhance care for at-risk groups, particularly veterans. The collaboration aims to utilize advanced therapeutic approaches to address the dual challenges of PTSD and addiction. Pilot results will guide the expansion of this offering to other demographics.
BioCorRx Inc. (BICX) announced significant advancements in its first quarter of 2022, including the initiation of a clinical trial for BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder. The recruitment for this Phase 1 study is a critical milestone. Additionally, the company reported a revenue increase due to a higher patient count in licensed clinics and growing participation in its UnCraveRx™ Weight Loss Management Program. Operating expenses were reduced by nearly 30%, showcasing effective cost management.
BioCorRx Inc. (OTCQB: BICX) has initiated the recruiting and enrollment process for its first-in-human clinical trial of BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder (OUD). This Phase 1, open-label study will assess the pharmacokinetics and safety of BICX104 against a marketed naltrexone injection. The trial will be conducted at the Orange County Research Center, led by Dr. Joel M. Neutel. The company enjoys active IND status and FDA acceptance for a 505(b)(2) pathway, potentially allowing for dual indication for OUD and Alcohol Use Disorder (AUD).
FAQ
What is the current stock price of Biocorrx (BICX)?
What is the market cap of Biocorrx (BICX)?
What does BioCorRx Inc. specialize in?
What is the BioCorRx Recovery Program?
What is BICX104?
How does BioCorRx address obesity?
What makes BioCorRx unique in the addiction treatment market?
What partnerships has BioCorRx formed to advance its treatments?
What challenges does BioCorRx aim to address in addiction treatment?
Does BioCorRx have any patented technologies?
What is the significance of the NIH HEAL Initiative® for BioCorRx?
How does BioCorRx contribute to public health?
